Open Outbreak

Drug-resistant bacteria and fungi

Also known as: Antimicrobial resistance, AMR, antibiotic resistance, antifungal resistance, multidrug-resistant organisms

Antimicrobial resistance, or AMR, means bacteria or fungi are no longer reliably stopped by medicines that used to work. It is not one single disease. It is a growing problem across many infections, from hospital bloodstream infections to resistant fungal outbreaks such as Candida auris. Resistance can arise through genetic change and then spread when resistant germs move between people, in healthcare settings, in the community, and through the wider environment. WHO says resistant, hypervirulent Klebsiella pneumoniae has now been reported in all six WHO regions, and that surveillance still misses much of the problem. For the public, the main point is simple: common infections can become harder to treat, treatment may need more toxic or less available drugs, and severe infections can become more dangerous. There is no vaccine against AMR itself, though some individual infections have vaccines. Control depends on infection prevention, careful antimicrobial use, rapid testing, and new medicines.

Key facts

TransmissionVaries by organism. Resistant bacteria and fungi spread through the same routes as their non-resistant forms, including direct contact, healthcare-associated spread, and sometimes community spread. Candida auris is described as healthcare-associated and highly transmissible. AMR itself is not a single route-specific disease.
Incubationunknown; AMR is not one disease and incubation depends on the underlying infection
Case fatalityunknown overall; severity and mortality depend on the organism, site of infection, patient risk factors, and whether effective treatment is available
Reproduction numberunknown; no single R0 applies because AMR covers many different organisms and settings
VaccineNo vaccine exists for AMR itself. Some infections caused by resistant organisms have pathogen-specific vaccines or vaccine candidates, but coverage is uneven.
TreatmentTreatment depends on laboratory susceptibility testing and the infection site. WHO notes the need for alternative antimicrobials for some last-line resistant infections, and new therapeutic options remain a priority.
ReservoirHumans, healthcare environments, and the wider environment can all act as reservoirs, depending on the organism. For Candida auris, hospitals and long-term care settings are important reservoirs.
Endemic regionsWorldwide. WHO reports resistant hypervirulent Klebsiella pneumoniae in all six WHO regions, and Candida auris has been reported globally.

Transmission

Drug-resistant bacteria and fungi do not spread by one single route. They spread in the same ways as the infections they come from. That can include direct contact between people, contaminated hands or equipment in healthcare, and sometimes wider community spread. What makes AMR different is that the germ carries resistance traits, so standard treatment may fail. The WHO notice on resistant, hypervirulent Klebsiella pneumoniae says spread can occur in both hospital and community settings, and highlights the need for standard and contact precautions, including isolation, when cases are identified. For Candida auris, recent reviews describe it as a healthcare-associated fungus that is highly transmissible and persistent, with important outbreak potential. In plain terms, AMR becomes more likely to matter when resistant germs can move easily through hospitals or care homes, where many people are already vulnerable and exposed to antibiotics.

Symptoms and severity

AMR does not cause one standard set of symptoms. The symptoms come from the infection itself: fever, cough, painful urination, wound infection, or signs of bloodstream infection, depending on where the germ is in the body. The extra danger is that the usual medicine may not work, so illness can last longer or become harder to control. WHO says resistant hypervirulent Klebsiella pneumoniae can cause severe invasive infections, including in healthy people, and that resistance to carbapenems, an important last-line antibiotic group, can leave clinicians with fewer options. For Candida auris, reviews say it is linked to high mortality, especially in very ill hospital patients, but exact fatality varies by study and setting. Because AMR covers many organisms, there is no single overall case-fatality rate that applies to all resistant infections.

Treatment and vaccines

There is no vaccine against AMR itself. Instead, treatment depends on identifying the germ and testing which drugs still work. WHO says resistant hypervirulent Klebsiella pneumoniae may require alternative antimicrobial treatment, and those options may not be available everywhere. That means access matters as much as science. For fungi such as Candida auris, reviews describe resistance to multiple antifungal classes, which can sharply limit choices. WHO’s 2024 bacterial priority pathogens study notes that at least 13 new antibiotics targeting bacterial priority pathogens were approved after the 2017 list, showing progress, but not a complete solution. For the public, the practical message is that good diagnosis, infection control, and careful prescribing are essential. New medicines help only when they are available, used appropriately, and supported by laboratory testing and surveillance.

Where it occurs

AMR is a worldwide problem, not a disease limited to one climate or region. The WHO Disease Outbreak News item from 2024 says resistant hypervirulent Klebsiella pneumoniae was reported in at least one country in all six WHO regions. WHO also stresses that the true scale is probably underestimated because many places lack the laboratory capacity needed to detect resistance and hypervirulence reliably. Reviews of Candida auris likewise describe global spread, with reports from more than 30 countries and strong links to healthcare settings such as intensive care units. This means the map of AMR partly reflects where testing is done, not just where the problem exists. Countries with weaker surveillance may look quieter than they really are. For readers, the safest assumption is that AMR can affect healthcare systems anywhere, while the specific organisms and resistance patterns differ by place and time.

Recent history

On this site’s archive, there are 0 past WHO-notice events indexed under the pathogen key “amr.” That does not mean the problem is new or absent. It reflects how AMR often appears as a cross-cutting threat rather than a single outbreak with one case count. WHO did publish a Disease Outbreak News item on 2024-07-31 about antimicrobial resistance in hypervirulent Klebsiella pneumoniae. In that report, WHO described sustained transmission over several years, reports from multiple countries, and a moderate global risk assessment because of surveillance gaps and limited information on community spread and disease burden. In the research literature, WHO’s 2024 bacterial priority pathogens work and its 2024 AMR research-priorities paper both show that AMR remains a major global health priority in bacteria and fungi. So the recent pattern is not one dramatic worldwide event, but a steady accumulation of hard-to-treat infections and concerning resistant strains.

What to watch

The main warning signs are clear. First, watch for resistant organisms appearing in new regions or more healthcare facilities, especially when laboratories confirm the same strain spreading between patients. Second, watch for stronger evidence of community transmission, not just hospital spread. WHO specifically notes uncertainty about the track and scale of community transmission for resistant hypervirulent Klebsiella pneumoniae. Third, watch for resistance to last-line drugs, such as carbapenems for some bacteria or multi-class resistance in fungi like Candida auris. Fourth, watch for weak laboratory capacity, because outbreaks can grow before they are recognized. Finally, watch medicine supply and pipeline issues: if effective drugs are scarce, unavailable, or too expensive, resistance becomes more dangerous. In short, AMR becomes more concerning when spread is wider, treatment choices are fewer, and surveillance cannot keep up.

Related outbreaks

Updated